Shanxi Medical University, Taiyuan, China.
Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Nurs Open. 2023 Aug;10(8):5453-5461. doi: 10.1002/nop2.1784. Epub 2023 Apr 26.
The aim of the study was to investigate the incidence of sleep disturbance and its relationship with anxiety and depression symptoms, social support and hope in breast cancer patients in China during chemotherapy.
A single-centre cross-sectional study.
A total of 329 breast cancer patients were selected via convenience sampling method before they began chemotherapy (n = 115), before the 5th week of chemotherapy (n = 117) or 1 month after chemotherapy ended (n = 97) and administered paper-and-pencil questionnaires to evaluate sleep quality, depression and anxiety symptoms, social support and hope. Risk factors significantly associated with sleep disturbance during bivariate were incorporated in the multivariate analysis. Bivariate analyses showed that age, menopausal status, depression and anxiety symptoms, emotional/informational support, tangible support, affectionate support, positive social interaction and total support were predictors of sleep disturbance.
Sleep disturbance was prevalent in breast cancer patients before (27.0%), during (32.5%) and after (39.2%) chemotherapy, with 37.4%, 41.9% and 52.6% of participants, respectively, reporting sleeping below the recommended 7 h. Only 8.6%-15.5% of patients reported taking sedative-hypnotic drugs during the chemotherapy. Multivariate analyses found that participants reporting clinically significant anxiety (HADS > 8) were 3.5 times more likely to report sleep disturbance (PSQI > 8) than participants without clinically significant anxiety, and each increment in emotional/informational support was associated with a 9.04% reduced risk of sleep disturbance. Moreover, age was an independent predictor of sleep disturbance during multivariate modelling.
本研究旨在调查中国乳腺癌患者化疗期间睡眠障碍的发生率及其与焦虑和抑郁症状、社会支持和希望的关系。
单中心横断面研究。
采用便利抽样法，在开始化疗前（n=115）、化疗第 5 周前（n=117）或化疗结束后 1 个月内（n=97），共选取 329 例乳腺癌患者，通过纸笔问卷评估睡眠质量、抑郁和焦虑症状、社会支持和希望。将与睡眠障碍相关的显著风险因素纳入多变量分析。二元分析显示，年龄、绝经状态、抑郁和焦虑症状、情感/信息支持、有形支持、亲情支持、积极的社会互动和总支持是睡眠障碍的预测因素。
乳腺癌患者在化疗前（27.0%）、化疗期间（32.5%）和化疗后（39.2%）均存在睡眠障碍，分别有 37.4%、41.9%和 52.6%的患者报告睡眠时间低于推荐的 7 小时。仅有 8.6%-15.5%的患者在化疗期间服用镇静催眠药。多变量分析发现，报告有临床显著焦虑（HADS＞8）的患者报告睡眠障碍（PSQI＞8）的可能性是无临床显著焦虑患者的 3.5 倍，每增加 1 分情感/信息支持，睡眠障碍的风险就降低 9.04%。此外，年龄是多变量模型中睡眠障碍的独立预测因素。
